{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:42:08Z","timestamp":1791726128661,"version":"4.3.4"},"reference-count":93,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tuberculosis Controllers Association. Representatives from the American Academy of Pediatrics, the Canadian Thoracic Society, the International Union Against Tuberculosis and Lung Disease, and the World Health Organization also participated in the development of the guideline. This guideline provides recommendations on the clinical and public health management of tuberculosis in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis. For all recommendations, literature reviews were performed, followed by discussion by an expert committee according to the Grading of Recommendations, Assessment, Development and Evaluation methodology. Given the public health implications of prompt diagnosis and effective management of tuberculosis, empiric multidrug treatment is initiated in almost all situations in which active tuberculosis is suspected. Additional characteristics such as presence of comorbidities, severity of disease, and response to treatment influence management decisions. Specific recommendations on the use of case management strategies (including directly observed therapy), regimen and dosing selection in adults and children (daily vs intermittent), treatment of tuberculosis in the presence of HIV infection (duration of tuberculosis treatment and timing of initiation of antiretroviral therapy), as well as treatment of extrapulmonary disease (central nervous system, pericardial among other sites) are provided. The development of more potent and better-tolerated drug regimens, optimization of drug exposure for the component drugs, optimal management of tuberculosis in special populations, identification of accurate biomarkers of treatment effect, and the assessment of new strategies for implementing regimens in the field remain key priority areas for research. See the full-text online version of the document for detailed discussion of the management of tuberculosis and recommendations for practice.<\/jats:p>","DOI":"10.1093\/cid\/ciw566","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T12:33:15Z","timestamp":1473683595000},"page":"853-867","source":"Crossref","is-referenced-by-count":280,"title":["Executive Summary: Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis"],"prefix":"10.1093","volume":"63","author":[{"given":"Payam","family":"Nahid","sequence":"first","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Dorman","sequence":"additional","affiliation":[{"name":"Johns Hopkins University 2 \u00a0 , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Alipanah","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pennan M.","family":"Barry","sequence":"additional","affiliation":[{"name":"3 \u00a0California Department of Public Health, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan L.","family":"Brozek","sequence":"additional","affiliation":[{"name":"McMaster University 4 \u00a0 , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adithya","family":"Cattamanchi","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lelia H.","family":"Chaisson","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Chaisson","sequence":"additional","affiliation":[{"name":"Johns Hopkins University 2 \u00a0 , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[{"name":"National Jewish Health 5 \u00a0 , Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgosia","family":"Grzemska","sequence":"additional","affiliation":[{"name":"World Health Organization 6 \u00a0 , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Higashi","sequence":"additional","affiliation":[{"name":"Tuberculosis Control Section 7 \u00a0 , San Francisco Department of Public Health, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S.","family":"Ho","sequence":"additional","affiliation":[{"name":"National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention 8 \u00a0 Division of Tuberculosis Elimination , , Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Hopewell","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salmaan A.","family":"Keshavjee","sequence":"additional","affiliation":[{"name":"Harvard Medical School 9 \u00a0 , Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lienhardt","sequence":"additional","affiliation":[{"name":"World Health Organization 6 \u00a0 , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Menzies","sequence":"additional","affiliation":[{"name":"McGill University 10 \u00a0 , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Merrifield","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Narita","sequence":"additional","affiliation":[{"name":"Tuberculosis Control Program, Seattle and King County Public Health, and University of Washington 12 \u00a0 , Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"O'Brien","sequence":"additional","affiliation":[{"name":"International Union Against TB and Lung Disease 13 \u00a0 Ethics Advisory Group , , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"University of Florida 14 \u00a0 , Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Raftery","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi","family":"Saukkonen","sequence":"additional","affiliation":[{"name":"Boston University 15 \u00a0 , Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Simon","family":"Schaaf","sequence":"additional","affiliation":[{"name":"16 \u00a0Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sotgiu","sequence":"additional","affiliation":[{"name":"University of Sassari 17 \u00a0 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Starke","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine 18 \u00a0 , Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Migliori","sequence":"additional","affiliation":[{"name":"11 \u00a0WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri Care and Research Institute, Tradate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vernon","sequence":"additional","affiliation":[{"name":"National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention 8 \u00a0 Division of Tuberculosis Elimination , , Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"2024062808202360300_CIW566C1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/rccm.200602-197ST","article-title":"An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations","volume":"174","author":"Schunemann","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202360300_CIW566C2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"10 suppl 2","key":"2024062808202360300_CIW566C3","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202360300_CIW566C4","doi-asserted-by":"crossref","first-page":"724","DOI":"10.5588\/ijtld.12.0083","article-title":"The chemotherapy of tuberculosis: past, present and future","volume":"16","author":"Mitchison","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202360300_CIW566C5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"2024062808202360300_CIW566C6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0041-3879(80)90060-4","article-title":"Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study","volume":"61","author":"Zierski","year":"1980","journal-title":"Tubercle"},{"key":"2024062808202360300_CIW566C7","doi-asserted-by":"crossref","first-page":"e63840","DOI":"10.1371\/journal.pone.0063840","article-title":"An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse","volume":"8","author":"Phillips","year":"2013","journal-title":"PLoS One"},{"key":"2024062808202360300_CIW566C8","first-page":"276","article-title":"Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy [in French]","volume":"53","author":"Aber","year":"1978","journal-title":"Bull Int Union Tuberc"},{"key":"2024062808202360300_CIW566C9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial","volume":"360","author":"Benator","year":"2002","journal-title":"Lancet"},{"key":"2024062808202360300_CIW566C10","volume-title":"Treatment of tuberculosis disease. Canadian Tuberculosis Standards","author":"Menzies","year":"2014","edition":"7th ed"},{"key":"2024062808202360300_CIW566C11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1164\/rccm.200208-951OC","article-title":"Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine","volume":"167","author":"Weiner","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"RR-11","key":"2024062808202360300_CIW566C12","first-page":"1","article-title":"Recommendations of the Advisory Council for the Elimination of Tuberculosis","volume":"44","author":"Essential components of a tuberculosis prevention and control program","year":"1995","journal-title":"MMWR Recomm Rep"},{"issue":"RR-12","key":"2024062808202360300_CIW566C13","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Taylor","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"2024062808202360300_CIW566C14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1473-3099(06)70628-4","article-title":"International standards for tuberculosis care","volume":"6","author":"Hopewell","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"2024062808202360300_CIW566C15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1183\/09031936.00203811","article-title":"European Union standards for tuberculosis care","volume":"39","author":"Migliori","year":"2012","journal-title":"Eur Respir J"},{"key":"2024062808202360300_CIW566C16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1513\/AnnalsATS.201401-004AR","article-title":"Updating the International Standards for Tuberculosis Care. Entering the era of molecular diagnostics","volume":"11","author":"Hopewell","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2024062808202360300_CIW566C17","article-title":"Managing tuberculosis patients and improving adherence","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"2024062808202360300_CIW566C18","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1371\/journal.pmed.0040238","article-title":"Patient adherence to tuberculosis treatment: a systematic review of qualitative research","volume":"4","author":"Munro","year":"2007","journal-title":"PLoS Med"},{"key":"2024062808202360300_CIW566C19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00129234-200211000-00005","article-title":"A ten-step process to develop case management plans","volume":"7","author":"Tahan","year":"2002","journal-title":"Lippincotts Case Manag"},{"key":"2024062808202360300_CIW566C20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2471\/BLT.06.035568","article-title":"Promoting adherence to tuberculosis treatment","volume":"85","author":"Garner","year":"2007","journal-title":"Bull World Health Organ"},{"key":"2024062808202360300_CIW566C21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2146\/ajhp050543","article-title":"Effect of pharmacist-led patient education on adherence to tuberculosis treatment","volume":"64","author":"Clark","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"2024062808202360300_CIW566C22","first-page":"1073","article-title":"A randomised trial of the impact of counselling on treatment adherence of tuberculosis patients in Sialkot, Pakistan","volume":"3","author":"Liefooghe","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202360300_CIW566C23","first-page":"CD006591","article-title":"Patient education and counselling for promoting adherence to treatment for tuberculosis","volume":"5","author":"M'Imunya","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202360300_CIW566C24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1077558705275416","article-title":"The impact of medical interpreter services on the quality of health care: a systematic review","volume":"62","author":"Flores","year":"2005","journal-title":"Med Care Res Rev"},{"key":"2024062808202360300_CIW566C25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0041-3879(81)90017-9","article-title":"A randomised study of two policies for managing default in out-patients collecting supplies of drugs for pulmonary tuberculosis in a large city in South India","volume":"62","author":"Krishnaswami","year":"1981","journal-title":"Tubercle"},{"key":"2024062808202360300_CIW566C26","first-page":"1444","article-title":"Tuberculosis treatment with mobile-phone medication reminders in northern Thailand","volume":"42","author":"Kunawararak","year":"2011","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2024062808202360300_CIW566C27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00005650-199404000-00006","article-title":"Automated telephone reminders in tuberculosis care","volume":"32","author":"Tanke","year":"1994","journal-title":"Med Care"},{"key":"2024062808202360300_CIW566C28","first-page":"CD006594","article-title":"Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment","volume":"11","author":"Liu","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202360300_CIW566C29","first-page":"349394","article-title":"TextTB: a mixed method pilot study evaluating acceptance, feasibility, and exploring initial efficacy of a text messaging intervention to support TB treatment adherence","volume":"2013","author":"Iribarren","year":"2013","journal-title":"Tuberc Res Treat"},{"key":"2024062808202360300_CIW566C30","first-page":"CD007952","article-title":"Material incentives and enablers in the management of tuberculosis","volume":"1","author":"Lutge","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202360300_CIW566C31","doi-asserted-by":"crossref","first-page":"b4248","DOI":"10.1136\/bmj.b4248","article-title":"Food incentives to improve completion of tuberculosis treatment: randomised controlled trial in Dili, Timor-Leste","volume":"339","author":"Martins","year":"2009","journal-title":"BMJ"},{"key":"2024062808202360300_CIW566C32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12879-015-0945-5","article-title":"Community-based directly observed therapy (DOT) versus clinic DOT for tuberculosis: a systematic review and meta-analysis of comparative effectiveness","volume":"15","author":"Wright","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2024062808202360300_CIW566C33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.279.12.943","article-title":"Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel","volume":"279","author":"Chaulk","year":"1998","journal-title":"JAMA"},{"key":"2024062808202360300_CIW566C34","first-page":"884","article-title":"DOT and timely treatment completion among Asian-born immigrant tuberculosis patients","volume":"9","author":"Liu","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202360300_CIW566C35","article-title":"A call for action on the tuberculosis elimination plan for the United States","author":"Stop TB USA Tuberculosis Elimination Plan Committee","year":"2010"},{"key":"2024062808202360300_CIW566C36","doi-asserted-by":"crossref","first-page":"e1000146","DOI":"10.1371\/journal.pmed.1000146","article-title":"Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis","volume":"6","author":"Menzies","year":"2009","journal-title":"PLoS Med"},{"key":"2024062808202360300_CIW566C37","doi-asserted-by":"crossref","first-page":"e1000150","DOI":"10.1371\/journal.pmed.1000150","article-title":"Standardized treatment of active tuberculosis in patients with previous treatment and\/or with mono-resistance to isoniazid: a systematic review and meta-analysis","volume":"6","author":"Menzies","year":"2009","journal-title":"PLoS Med"},{"key":"2024062808202360300_CIW566C38","first-page":"501","article-title":"Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993\u20132002","volume":"9","author":"LoBue","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202360300_CIW566C39","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1001\/archinte.168.18.1984","article-title":"Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003","volume":"168","author":"Hoopes","year":"2008","journal-title":"Arch Intern Med"},{"key":"2024062808202360300_CIW566C40","doi-asserted-by":"crossref","first-page":"e22927","DOI":"10.1371\/journal.pone.0022927","article-title":"Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994\u20132009","volume":"6","author":"Jenkins","year":"2011","journal-title":"PLoS One"},{"key":"2024062808202360300_CIW566C41","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1542\/peds.2015-0172","article-title":"Global and regional burden of isoniazid-resistant tuberculosis","volume":"136","author":"Yuen","year":"2015","journal-title":"Pediatrics"},{"key":"2024062808202360300_CIW566C42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0041-3879(80)90038-0","article-title":"Pyridoxine supplementation during isoniazid therapy","volume":"61","author":"Snider","year":"1980","journal-title":"Tubercle"},{"key":"2024062808202360300_CIW566C43","first-page":"260","article-title":"The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis","volume":"8","author":"Visser","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202360300_CIW566C44","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/ajrccm\/147.4.1062","article-title":"Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months","volume":"147","author":"Mitchison","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202360300_CIW566C45","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.rmed.2014.01.010","article-title":"Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen","volume":"108","author":"Jo","year":"2014","journal-title":"Respir Med"},{"key":"2024062808202360300_CIW566C46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1473-3099(10)70071-2","article-title":"Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis","volume":"10","author":"Horne","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2024062808202360300_CIW566C47","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1164\/rccm.200407-905OC","article-title":"A nested case-control study on treatment-related risk factors for early relapse of tuberculosis","volume":"170","author":"Chang","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202360300_CIW566C48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1164\/rccm.200511-1834OC","article-title":"Lack of weight gain and relapse risk in a large tuberculosis treatment trial","volume":"174","author":"Khan","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202360300_CIW566C49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1741-7015-9-81","article-title":"The impact of diabetes on tuberculosis treatment outcomes: a systematic review","volume":"9","author":"Baker","year":"2011","journal-title":"BMC Med"},{"key":"2024062808202360300_CIW566C50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1378\/chest.14-0918","article-title":"Optimal duration of anti-TB treatment in patients with diabetes: nine or six months?","volume":"147","author":"Wang","year":"2015","journal-title":"Chest"},{"key":"2024062808202360300_CIW566C51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1183\/09031936.00114214","article-title":"Smoking adversely affects treatment response, outcome and relapse in tuberculosis","volume":"45","author":"Leung","year":"2015","journal-title":"Eur Respir J"},{"key":"2024062808202360300_CIW566C52","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/cid\/cis630","article-title":"An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection","volume":"55","author":"Ahmad Khan","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024062808202360300_CIW566C53","volume-title":"Core curriculum on tuberculosis: what the clinician should know.","author":"Centers for Disease Control and Prevention","year":"2013","edition":"6th ed"},{"key":"2024062808202360300_CIW566C54","first-page":"806","article-title":"Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis","volume":"14","author":"Lin","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202360300_CIW566C55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N Engl J Med"},{"key":"2024062808202360300_CIW566C56","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202360300_CIW566C57","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1086\/650576","article-title":"Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity","volume":"50","author":"Sharma","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024062808202360300_CIW566C58","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1086\/654806","article-title":"The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate","volume":"51","author":"Chang","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024062808202360300_CIW566C59","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium","volume":"353","author":"Vernon","year":"1999","journal-title":"Lancet"},{"key":"2024062808202360300_CIW566C60","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1164\/rccm.200503-417OC","article-title":"Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis","volume":"173","author":"Burman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202360300_CIW566C61","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024062808202360300_CIW566C62","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/cid\/ciu674","article-title":"Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy","volume":"59","author":"Narendran","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024062808202360300_CIW566C63","doi-asserted-by":"crossref","first-page":"a257","DOI":"10.1136\/bmj.a257","article-title":"Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial","volume":"337","author":"Nunn","year":"2008","journal-title":"BMJ"},{"key":"2024062808202360300_CIW566C64","doi-asserted-by":"crossref","first-page":"128C","DOI":"10.2471\/BLT.11.093260","article-title":"Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis","volume":"90","author":"Suthar","year":"2012","journal-title":"Bull World Health Organ"},{"key":"2024062808202360300_CIW566C65","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(99)03465-0","article-title":"Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial","volume":"353","author":"Wiktor","year":"1999","journal-title":"Lancet"},{"key":"2024062808202360300_CIW566C66","article-title":"Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","year":"2014"},{"key":"2024062808202360300_CIW566C67","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/cid\/ciu094","article-title":"Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Masur","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024062808202360300_CIW566C68","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/QAI.0000000000000030","article-title":"Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs","volume":"65","author":"Luetkemeyer","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024062808202360300_CIW566C69","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","article-title":"Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings","volume":"8","author":"Meintjes","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2024062808202360300_CIW566C70","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","article-title":"Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome","volume":"24","author":"Meintjes","year":"2010","journal-title":"AIDS"},{"key":"2024062808202360300_CIW566C71","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(87)91127-5","article-title":"Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei","volume":"2","author":"Strang","year":"1987","journal-title":"Lancet"},{"key":"2024062808202360300_CIW566C72","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(88)92415-4","article-title":"Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei","volume":"2","author":"Strang","year":"1988","journal-title":"Lancet"},{"key":"2024062808202360300_CIW566C73","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/heart.84.2.183","article-title":"Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients","volume":"84","author":"Hakim","year":"2000","journal-title":"Heart"},{"key":"2024062808202360300_CIW566C74","first-page":"2534","article-title":"Immunotherapy for tuberculous pericarditis","volume":"371","author":"Mayosi","year":"2014","journal-title":"N Engl J Med"},{"key":"2024062808202360300_CIW566C75","first-page":"233","article-title":"Experience with adjunctive corticosteroids in managing tuberculous pericarditis","volume":"17","author":"Reuter","year":"2006","journal-title":"Cardiovasc J S Afr"},{"key":"2024062808202360300_CIW566C76","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1056\/NEJMe1409356","article-title":"Immunotherapy for tuberculous pericarditis","volume":"371","author":"Chaisson","year":"2014","journal-title":"N Engl J Med"},{"key":"2024062808202360300_CIW566C77","article-title":"2015 Red Book: Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics. Committee on Infectious Diseases","year":"2015","edition":"30th ed"},{"key":"2024062808202360300_CIW566C78","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jinf.2009.06.011","article-title":"British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children","volume":"59","author":"Thwaites","year":"2009","journal-title":"J Infect"},{"key":"2024062808202360300_CIW566C79","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(55)90003-9","article-title":"Tuberculous meningitis treated with cortisone","volume":"268","author":"Ashby","year":"1955","journal-title":"Lancet"},{"key":"2024062808202360300_CIW566C80","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-70-1-39","article-title":"Dexamethasone in tuberculous meningitis. Relationship of cerebrospinal fluid effects to therapeutic efficacy","volume":"70","author":"O'Toole","year":"1969","journal-title":"Ann Intern Med"},{"key":"2024062808202360300_CIW566C81","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1542\/peds.56.6.1050","article-title":"Mortality from tuberculous meningitis reduced by steroid therapy","volume":"56","author":"Escobar","year":"1975","journal-title":"Pediatrics"},{"key":"2024062808202360300_CIW566C82","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/0035-9203(83)90195-5","article-title":"The use of dexamethasone in preventing ocular complications in tuberculous meningitis","volume":"77","author":"Girgis","year":"1983","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024062808202360300_CIW566C83","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00006454-199103000-00002","article-title":"Dexamethasone adjunctive treatment for tuberculous meningitis","volume":"10","author":"Girgis","year":"1991","journal-title":"Pediatr Infect Dis J"},{"key":"2024062808202360300_CIW566C84","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0962-8479(94)90009-4","article-title":"Randomized controlled trial of dexamethasone in tuberculous meningitis","volume":"75","author":"Kumarvelu","year":"1994","journal-title":"Tuber Lung Dis"},{"key":"2024062808202360300_CIW566C85","first-page":"83","article-title":"Corticosteroid in tuberculous meningitis","volume":"79","author":"Chotmongkol","year":"1996","journal-title":"J Med Assoc Thai"},{"key":"2024062808202360300_CIW566C86","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1086\/515543","article-title":"Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature","volume":"25","author":"Dooley","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2024062808202360300_CIW566C87","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1542\/peds.99.2.226","article-title":"Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis","volume":"99","author":"Schoeman","year":"1997","journal-title":"Pediatrics"},{"key":"2024062808202360300_CIW566C88","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites","year":"2004","journal-title":"N Engl J Med"},{"key":"2024062808202360300_CIW566C89","first-page":"CD002244","article-title":"Corticosteroids for managing tuberculous meningitis","author":"Prasad","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202360300_CIW566C90","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1179\/000349809X12502035776315","article-title":"Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis","volume":"103","author":"Malhotra","year":"2009","journal-title":"Ann Trop Med Parasitol"},{"key":"2024062808202360300_CIW566C91","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(12)70321-3","article-title":"Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis","volume":"13","author":"Critchley","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2024062808202360300_CIW566C92","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5588\/ijtld.14.0798","article-title":"The impact of sputum quality on tuberculosis diagnosis: a systematic review","volume":"19","author":"Ho","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202360300_CIW566C93","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1164\/ajrccm\/139.5.1090","article-title":"Presumptive diagnosis and treatment of pulmonary tuberculosis based on radiographic findings","volume":"139","author":"Gordin","year":"1989","journal-title":"Am Rev Respir Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/63\/7\/853\/58355830\/ciw566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/63\/7\/853\/58355830\/ciw566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T04:21:23Z","timestamp":1719548483000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/63\/7\/853\/2197067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":93,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,9,1]]},"published-print":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciw566","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,10,1]]},"published":{"date-parts":[[2016,9,1]]}}}